Lyell Immunopharma Inc (LYEL)

$0.43 -0.01 (-1.23%)
Market Cap 128.04M
Revenue (ttm) 60,000.00
Net Income (ttm) -342.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -571,650.00%
Debt to Equity Ratio 0.00
Volume 1,131,800
Avg Vol 1,059,154
Day's Range N/A - N/A
Shares Out 295.28M
Stochastic %K 34%
Beta -0.26
Analysts Hold
Price Target $0.80

Latest News on LYEL

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Apr 15, 2025, 9:00 AM EDT - 6 days ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 4:05 PM EDT - 5 weeks ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 2 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Jan 9, 2025, 9:00 AM EST - 3 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Dec 9, 2024, 9:00 PM EST - 4 months ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 9:30 AM EST - 5 months ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 6 months ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25, 2024, 9:24 AM EDT - 6 months ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 24, 2024, 4:00 PM EDT - 6 months ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 7 months ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Sep 24, 2024, 4:05 PM EDT - 7 months ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 28, 2024, 4:05 PM EDT - 8 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 7, 2024, 4:05 PM EDT - 9 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 26, 2024, 7:00 AM EDT - 10 months ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 11 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 10, 2023, 2:23 PM EST - 1 year ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 9, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Nov 7, 2023, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 31, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 26, 2023, 9:29 AM EDT - 1 year ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jul 5, 2023, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 15, 2022, 7:00 AM EST - 2 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Dec 1, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 10, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Nov 8, 2022, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Nov 7, 2022, 8:05 AM EST - 2 years ago

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Oct 6, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 2 years ago

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Sep 28, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Sep 12, 2022, 3:00 AM EDT - 2 years ago

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

Aug 30, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

Aug 4, 2022, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

Jun 7, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

May 2, 2022, 4:30 PM EDT - 3 years ago

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Mar 29, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 8, 2022, 4:45 PM EST - 3 years ago

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting